drugset / Trial / NCT06118372

Recombinant vWF Concentrate and ECMO

NCT06118372

Phase 1 Recruiting 12 enrolled University of Virginia
NaSingle-groupOpen-labelTreatment

Summary

Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS). Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes platelet adhesion and thrombus formation. This study is a phase I study, where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a single time. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of recombinant vWF in adult ECMO patients.

Timeline

Start
2024-10-03
Primary completion
2026-12-31
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant von Willebrand Factor Protein / enzyme biologic 50 iu/kg Intravenous